Five firms cut EyePoint Pharmaceuticals inside a few sessions, all of them reading the same trial readout. That is what a revision cluster looks like when the trigger is binary: coverage does not drift, it relocates. The rest of this week's screen was less uniform, and considerably more instructive for it, because in three of the five names the rating and the price target moved in opposite directions.
Using FMP's Stock News API alongside the Stock Grades API, this article works through the five names where multiple firms acted inside the same window, and separates the clusters built on a single fact from those where analysts were arguing about price rather than about the business.
Key Takeaways
- Revision count told us where to look; the relationship between the rating change and the target change told us what had actually been rewritten.
- EyePoint's five downgrades paired one-notch rating moves with target cuts of roughly 90%, the signature of an approval scenario being removed from a model rather than a business being repriced.
- Workday was downgraded while its target was raised, and Analog Devices was upgraded on a lower multiple: two inverted shapes that a revision-count screen cannot see.
- Portland General Electric was upgraded through an earnings miss, because both notes were underwriting a financing structure rather than a quarter.
The Five Names Where Coverage Moved Together
EyePoint Pharmaceuticals (EYPT) - 5 Downgrades
EyePoint absorbed five downgrades in short order. Chardan moved from Buy to Neutral and cut its target to $5.00 from $65.00. RBC Capital went from Outperform to Sector Perform with a $5.00 target, down from $37.00. H.C. Wainwright shifted from Buy to Neutral, JPMorgan from Overweight to Neutral, and Cantor Fitzgerald from Overweight to Neutral. The trigger was the 17 August topline from LUGANO, the first of two pivotal Phase 3 trials for DURAVYU 2.7mg in wet AMD, which missed its primary non-inferiority endpoint in the full analysis set.
The proportions matter more than the direction here. A move from Buy to Neutral is one notch. A move from $65 to $5 is a 92% reduction. That asymmetry is the tell: the firms were not marking down a commercial forecast, they were deleting a probability-weighted approval scenario and leaving behind roughly the residual value of a second attempt. The clinical detail supports that reading rather than contradicting it. Secondary endpoints held, with a 42% reduction in treatment burden against on-label aflibercept at p<0.0001, around two fewer injections through week 56, and a safety profile with no insert migration reported. An ad hoc analysis excluding nine patients, about 4% of the cohort, who lost fifteen or more letters for reasons the company attributes to causes unrelated to wet AMD did clear non-inferiority at a nominal p=0.0096. Post hoc is not registrational, and the analysts priced it accordingly.
What makes the cluster worth keeping on file is where the firms stopped. Four of the five landed on Neutral rather than moving to Sell, which is consistent with waiting rather than exiting: LUCIA carries an identical design, topline is guided to the fourth quarter of 2026, and the company's stated NDA target of the first half of 2027 is contingent on it. Second-quarter results reported on 5 August showed a $94.5 million net loss against $180 million in cash and marketable securities, with runway guided into the fourth quarter of 2027, so the balance sheet reaches the second readout. FMP's Historical Stock Grades API is the right instrument for this kind of event, because it preserves the sequence and the timestamps: knowing which firm moved first, and how far behind the others followed, distinguishes a considered reassessment from a same-morning reflex.
Merck (MRK) - Two Downgrades, One Upgrade
Merck produced the week's most contradictory cluster. Morgan Stanley upgraded from Equalweight to Overweight and lifted its target to $179.00 from $116.00, applying a 17x multiple against 11x previously, on the strength of the Phase 3 INTerpath-001 readout in adjuvant melanoma and follow-on Sac-TMT data in lung and endometrial cancer. RBC Capital moved the other way, from Outperform to Sector Perform, while raising its target to $150.00 from $142.00. Separately, UBS downgraded Merck from Buy to Neutral, citing bioprocess consumables demand and the recently announced Bio-Techne acquisition.
Strip out the noise and the disagreement is narrow. Both US-facing firms landed within twenty dollars of each other on target, and both accept the same operating picture. RBC downgraded while raising its number, which is a statement about risk and reward after a run rather than about the franchise. Morgan Stanley's move was almost entirely multiple: the target rose by 54% while the rerating from 11x to 17x accounts for nearly all of it. The underlying question is unchanged and concentrated. Keytruda and its subcutaneous form generated $8.4 billion in the second quarter, and the franchise represented roughly half of total 2025 revenue, so every new product cycle is being measured against a loss-of-exclusivity hole rather than against its own market.
That is what gives the INTerpath-001 result its weight. Intismeran autogene is an individualised mRNA neoantigen therapy encoding up to 34 patient-specific targets manufactured per patient, with economics split evenly between the two partners, and the trial was stopped at its first interim analysis with hazard ratios withheld for a medical meeting. Merck's own second-quarter print on 4 August raised full-year revenue guidance while reducing non-GAAP EPS guidance purely on acquisition-related charges from the Cidara and Terns transactions, a distinction that matters when reading the headline. FMP's Revenue Product Segmentation API is the dataset that makes this concrete: it sizes the Keytruda concentration against the rest of the portfolio, which is the only way to judge whether a positive readout is material to the revenue base or simply encouraging.
Workday (WDAY) - 2 Downgrades
Workday drew two downgrades on 17 August. Deutsche Bank moved from Buy to Hold while raising its target to $220.00 from $180.00, stating explicitly that the call was about valuation and not about deteriorating fundamentals. Its note cited a roughly 26% advance between 1 June and 14 August against an average decline of about 4% across ServiceNow, Salesforce, Autodesk, Adobe and Intuit over the same stretch. BTIG cut from Buy to Neutral the same day.
A downgrade accompanied by a higher target is the cleanest signal on this week's screen. It says the analyst's estimates did not move and the price did. Nothing in the last reported quarter argues otherwise: revenue of $2.542 billion grew 13.5%, subscription revenue rose 14.3%, twelve-month cRPO reached $8.806 billion for 15.5% growth, and non-GAAP operating margin improved to 31.8% from 30.2%, with full-year subscription guidance reiterated and margin guidance raised. None of that produces a 26% move over ten weeks.
What produced it was reported takeover interest. Press accounts on 13 August described Silver Lake in talks over a take-private, the shares were halted and then closed roughly 25% higher, and no agreement, price, financing or exclusivity has been confirmed by either party since. So the cluster is not measuring software fundamentals at all: it is measuring deal probability, with a co-founder back in the chief executive seat since February as part of the context. For a reader trying to keep the two apart, FMP's Price Target Summary API is the useful lens, because it reports target averages and note counts across one-month, three-month and twelve-month windows, which makes it possible to see targets climbing while the rating distribution deteriorates. The operating variable still worth tracking underneath the deal noise is agent adoption, with more than 4,000 customers now using at least one Workday-built agent, and whether that converts into net subscription revenue.
Analog Devices (ADI) - 2 Upgrades
Analog Devices was upgraded twice on 20 August, the day after its fiscal third-quarter report. Seaport Global Securities moved from Neutral to Buy with a $425.00 target, framing the change around a conservative management team meaningfully raising its own forecasts, with lean inventories and lengthening lead times across most end markets. Bernstein SocGen Group went from Market Perform to Outperform and lifted its target to $465.00 from $430.00, describing itself as having been on the analog sidelines on valuation and now seeing risk and reward skewed enough to move.
The quarter behind the upgrades was unambiguous. Revenue of $4.02 billion grew 40% year over year, adjusted EPS rose 68%, and operating margin expanded 780 basis points to 50.0%, with industrial up 53% and communications up 84%. But the sentence that changed the models came from the call rather than the release: management now estimates its 2030 serviceable addressable market in data centre and energy at roughly double its own prior-year estimate. Data centre already accounts for about 80% of communications revenue and grew more than 100%, and management characterised power availability rather than silicon as the binding constraint on further AI buildout.
There is a detail in the Bernstein note that repays attention. Its target went up while its applied multiple came down, from 28x to 25x. That means the entire target increase is earnings and none of it is rerating, which is a more durable basis for an upgrade than the reverse and a useful contrast with the Merck cluster above. On the supply side, days of inventory at 156, channel weeks below the stated six-to-seven-week target, and a book-to-bill above 1.0 after nine consecutive quarters of above-seasonal growth form the pattern analysts read as early-cycle. It is also the pattern that creates the hardest comparisons a year out, which is the thing to monitor rather than the headline growth rate. FMP's Earnings Call Transcript API is where this story is actually recoverable, since the addressable-market revision and the power-constraint framing appear in the prepared remarks and the question-and-answer, not in the earnings release.
Portland General Electric Company (POR) - 2 Upgrades
Portland General Electric received two upgrades tied to a regulatory milestone rather than to operating results. Wells Fargo moved from Equal Weight to Overweight with a $58.00 target, up from $51.00, and Ladenburg Thalmann went from Neutral to Buy with a $48.50 target. Both follow the 12 August disclosure of a stipulation with Oregon Public Utility Commission staff recommending approval of the company's holding-company reorganisation, carrying a $45 million commitment: $40 million in customer rate credits over three years and $5 million for clean energy and related initiatives. A final order was targeted for 25 August. Intervenors AWEC and CUB have not signed on.
This cluster is unusual because it arrived through a miss. The second-quarter report on 7 August delivered non-GAAP earnings of $0.64 against a consensus closer to $0.74, on revenue below expectations, with full-year adjusted EPS guidance of $3.33 to $3.53 reaffirmed. Neither upgrade engages with that quarter. Both are underwriting a financing structure: Wells Fargo's arithmetic has the holding company replacing roughly $1.05 billion of prospective request-for-proposal equity, modelling $200 million against the $1.25 billion a conventional fifty-fifty funding mix would require, and lifting its 2026 to 2030 EPS growth rate to about 7.9%, roughly 200 basis points above consensus. The ring-fencing terms are the substance: a minimum 45% common equity ratio at the utility, separate credit ratings, commission approval for transfers above $1 million, and a golden share held by an independent third party.
The Ladenburg target sits below the prevailing share price, which is worth noticing rather than dismissing: the two notes agree on the regulatory outcome and disagree sharply on what it is worth. Underneath both sits demand rather than rate design. Industrial load grew 11.2% year over year on high-tech and data centre consumption while residential and commercial were broadly flat, and the commission acknowledged the all-source RFP shortlist in late May with contract execution expected by early 2027. The question the data suggests is worth monitoring is not the rate case but who funds the resulting equity requirement. FMP's SEC Filings API is the practical entry point, because the stipulation terms, the equity floor and the golden-share mechanism live in the 8-K itself and are flattened out of every secondary summary.
Reading Density Against Direction
Five clusters, and four genuinely different mechanisms underneath them. EyePoint was a fact being removed, with one-notch rating changes carrying target cuts near 90%. Merck was multiple expansion, with one firm downgrading while raising its number. Workday was deal probability wearing the clothes of a valuation call. Analog Devices was earnings without rerating. Portland General Electric was a capital-structure argument that survived a weak quarter untouched. Ranked by revision count, EyePoint dominates and the other four look like noise. Ranked by what the revisions actually changed, EyePoint is the least interesting of the five, because a binary readout produces exactly the response you would predict.
The more useful reading is directional consistency. When a rating falls and the target rises, the analyst is telling you the estimates held and the price ran. When a target rises while the applied multiple falls, the increase is earnings and therefore harder to reverse. Those two shapes appeared three times on this screen, and neither is visible in a count. Building the check is mechanical: FMP's Ratings Snapshot API establishes where the distribution currently stands, the Historical Stock Grades API supplies the sequence and timing of the moves, and the Price Target Summary API reports target averages and note counts across rolling windows so that rating drift and target drift can be compared rather than conflated.
From there the test is whether the revision reached the model. FMP's Financial Estimates API shows whether revenue, EBITDA and EPS lines moved or only the rating did, which is the difference between a reset and a repositioning. Where the thesis depends on surviving a wait, as with EyePoint's second pivotal trial or Portland General Electric's funding requirement, the Financial Scores API and the Enterprise Values API answer a narrower and more decisive question: does the balance sheet reach the catalyst. And where the catalyst is a document rather than a number, the SEC Filings API and the Earnings Call Transcript API return the primary text, which is where Analog Devices' addressable-market revision and Portland General's equity floor both originate.
None of these datasets is interesting alone. What makes the combination work is that a revision cluster is a question, not an answer, and answering it requires ratings, targets, estimates, statements, filings and transcript language to sit in one frame with consistent timestamps, which is the practical reason the breadth of coverage available through FMP matters more here than any single endpoint. Held together that way, the five clusters above stop looking like a list of sentiment changes and start reading as five different statements about which part of the model stopped being reliable.
Turning Analyst Revisions Into a Structured Research Workflow
Analyst ratings only become actionable when you stop treating them as isolated headlines and start handling them as structured data. The goal is straightforward: capture changes as they happen, standardize them, and then connect those changes back to real-world events. Before anything else, make sure your API key is active and ready to run.
1. Pull Latest Analyst Ratings
Begin with a fresh pull from the Stock News API. This endpoint aggregates recent market-moving headlines, including upgrades and downgrades. It's the fastest way to establish a baseline of who changed their view and when, without needing to scrape multiple sources.
Endpoint:
|
https://financialmodelingprep.com/stable/news/stock-latest?page=0&limit=20&apikey=YOUR_API_KEY |
Sample Response:
|
[ { "symbol": "INSG", "publishedDate": "2025-02-03 23:53:40", "publisher": "Seeking Alpha", "title": "Q4 Earnings Release Looms For Inseego, But Don't Expect Miracles", "image": "...", "site": "seekingalpha.com", "text": "Inseego's Q3 beat was largely due to a one-time debt restructuring gain, not sustainable earnings growth, raising concerns about future performance. The sale of its telematics business for $52 million allows INSG to focus on North America, but it remains to be seen if this was wise. Despite improved margins and reduced debt, Inseego's revenue growth is insufficient, and its high stock price remains unjustifiable for new investors.", "url": "https://seekingalpha.com/article/4754485-inseego-stock-q4-earnings-preview-monitor-growth-margins-closely" } ] |
2. Isolate Rating Changes
From that initial feed, filter for entries that explicitly reference upgrades or downgrades. This step is about narrowing the universe—identifying which tickers are actually seeing analyst activity versus general news flow. Once you have that subset, you're ready to move from raw headlines to structured tracking.
3. Quantify the Activity
For each ticker identified, call the Stock Grades API to retrieve the latest analyst actions tied specifically to that name. This is where the workflow shifts from collection to measurement.
Group the results by ticker and separate upgrades from downgrades. Single mentions tend to be incidental; repeated actions across multiple firms indicate something more deliberate. This aggregation step is what surfaces clusters—names where sentiment is actively being recalibrated.
4. Map the Catalyst
Once the high-activity names are clear, the next step is attribution. Use the Search Stock News API to pull company-specific headlines and align rating changes with underlying developments—earnings releases, M&A announcements, regulatory updates, or sector-wide shifts.
Endpoint:
|
https://financialmodelingprep.com/stable/news/stock?symbols=AAPL&apikey=YOUR_API_KEY |
Example Workflow: Finding the “Most Active” Stocks
- Pull a rolling seven-day window of headlines from the Stock News API and filter for upgrades/downgrades.
- Extract tickers that appear at least once with a rating change.
- For each ticker, query the Stock Grades API to retrieve the full set of recent analyst actions.
- Count total upgrades and downgrades per name.
- Prioritize tickers with three or more revisions (or another threshold aligned with your coverage).
- Run those tickers through the Search Stock News API to line up rating shifts with the underlying catalyst.
Scaling Analyst Workflows Across the Organization
Workflows built around analyst revisions rarely remain isolated for long once they begin producing repeatable signal quality. Inside most firms, the transition usually starts when a handful of analysts consistently surface actionable sentiment shifts earlier than the broader desk — not because they have access to different information, but because their process for structuring and contextualizing that information is more systematic. Over time, those workflows tend to move from individual notebooks and spreadsheets into shared operating infrastructure.
That evolution changes the role of the data itself. Analyst revisions stop functioning as scattered research notes and become part of a governed internal framework that can be referenced across research, portfolio management, and risk teams simultaneously. Centralized dashboards replace duplicated manual tracking, standardized query logic reduces interpretation drift between teams, and structured datasets create an audit trail around how sentiment changes were identified and interpreted. The operational benefit is not simply speed — it is consistency. When multiple desks are evaluating the same revision clusters against the same underlying financial and market data, internal discussions become materially less fragmented.
In practice, analysts often become the internal champions driving that standardization effort. After pressure-testing workflows across multiple earnings cycles, they begin codifying the inputs that proved most reliable: revision velocity, estimate changes, target dispersion, earnings transcript language, sector-relative performance, and catalyst alignment. Once standardized, those inputs become reusable across broader coverage universes rather than dependent on individual institutional knowledge. That continuity becomes increasingly important as coverage rotates, teams expand, or macro conditions force firms to reevaluate exposure across sectors quickly.
Infrastructure becomes increasingly relevant at that stage because scaling a workflow across teams requires more than simply increasing API usage. The underlying data pipelines, timestamps, outputs, and revision histories need to remain consistent and traceable across users and mandates. The Financial Modeling Prep Enterprise plan tend to fit into this layer less as standalone data products and more as centralized coordination systems — enabling firms to maintain shared reference frameworks as analyst sentiment, earnings revisions, and positioning data evolve over time.
Where the Framework Moves Before the Numbers Do
The most informative revisions this week were not the loudest ones: they were the ones where the rating and the target disagreed, because that disagreement locates the assumption being rewritten. Reading FMP's Stock News API and Stock Grades API together keeps that distinction visible, which is what turns a cluster of headlines into a dated record of when consensus changed its mind and about what.
For additional trading ideas backed by data, explore: Weekly Signals Desk | Price-Target Gaps Identified via the FMP API (Aug 10-14)
Disclosure: Signals Desk content is provided for informational and analytical purposes only and does not constitute investment advice or trade recommendations. The analysis reflects interpretation of market data and publicly disclosed or third-party information, including data accessed via Financial Modeling Prep APIs, at the time of publication. Signals discussed are probabilistic, can be wrong, and may change as market conditions and consensus data evolve. This content should be considered alongside broader research, individual objectives, and risk assessment.
